Publications by authors named "Elisa Lapadula"
Introduction: The GENCOV study sought to evaluate serological differences between individuals with differing COVID-19 severity and outcomes. We assessed the SARS-CoV-2 antibody response of GENCOV participants cross-sectionally 1-, 6-, and 12-months following COVID-19 diagnosis to identify patient factors associated with more robust and durable humoral immune responses.
Materials And Methods: COVID-19 patients and a control cohort of vaccinated infection-naïve participants were recruited at hospital sites across the Greater Toronto Area in Ontario, Canada.
Article Synopsis
- Novel genome sequencing (GS) presents new chances to share results with healthy people, leading to a need for effective genetic counseling methods.
- A study with 466 participants used a genomic counseling model (GCM) that included a digital platform and webinars, showing that knowledge about genetics improved and decisional conflict (uncertainty in decision-making) decreased after the counseling.
- Most participants (86%) wanted to learn all GS findings after the counseling, indicating that the GCM effectively informed the general public and helped them feel more confident in decisions about genetic information.
Background: GENCOV is a prospective, observational cohort study of COVID-19-positive adults. Here, we characterize and compare side effects between COVID-19 vaccines and determine whether reactogenicity is exacerbated by prior SARS-CoV-2 infection.
Methods: Participants were recruited across Ontario, Canada.
The GENCOV study aims to identify patient factors which affect COVID-19 severity and outcomes. Here, we aimed to evaluate patient characteristics, acute symptoms and their persistence, and associations with hospitalization. Participants were recruited at hospital sites across the Greater Toronto Area in Ontario, Canada.
View Article and Find Full Text PDFRapid advancements of genome sequencing (GS) technologies have enhanced our understanding of the relationship between genes and human disease. To incorporate genomic information into the practice of medicine, new processes for the analysis, reporting, and communication of GS data are needed. Blood samples were collected from adults with a PCR-confirmed SARS-CoV-2 (COVID-19) diagnosis (target N = 1500).
View Article and Find Full Text PDF